Merck KGaA 'reconsidering' further development of Matuzumab in colorectal cancer |
|
|
|
Published
:
Wed, 29 Aug 2007 07:10
|
FRANKFURT (Thomson Financial) - Merck KGaA said its division Merck Serono's Phase II trial of Matuzumab to treat metastatic colorectal cancer (mCRC) did not meet its predefined endpoint, adding it is are considering' further development of the drug.Matuzumab is being co-developed and co-commercialised jointly by Merck Serono and Takeda.'Both companies share the view that the study results in mCRC do not meet expectations,' Merck said.However the two companies will continue to study the drug in other tumours, including non-small cell lung cancer.maria.sheahan@thomson.commas/ejpCOPYRIGHTCopyright AFX News Limited 2007. All rights reserved.The copying, republication or redistribution of AFX News Content, including by framing or similar means, is expressly prohibited without the prior written consent of AFX News.
|
|
|
|
|
|
|
| Stock
Quotes * |
|
NASDAQ
|
|
1617.01 |
+17.95 (
1.13 %)
|
| SYMBOL (
2009-01-08 ) |
| LAST |
CHANGE
|
| SYMBOL (
2009-01-08 )
|
| LAST |
CHANGE
|
| SYMBOL (
2009-01-08 )
|
| LAST |
CHANGE
|
|
|
Print this Story
Biomira, Merck KGaA sign new supply agreement on Stimuvax 